Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation

Inclusion Criteria:

* ALL or high grade NHL that is Stage III or IV and has relapsed or is considered to be primary refractory disease.
* Myelodysplastic syndrome.
* AML after first relapse or with primary refractory disease.
* CML hemophagocytic lymphohistiocytosis (HLH)
* Familial hemophagocytic lymphohistiocytosis (FLH)
* Viral-associated hemophagocytic syndrome (VAHS)
* X-linked lymphoproliferative disease (XLP)
* Patients with Severe chronic active Epstein Barr virus infection (SCAEBV) with predilection for T- or NK-cell malignancy
* Lack of suitable conventional donor (i.e. 5/6 or 6/6 related or 5/6 or 6/6 unrelated donor) or presence of a rapidly progressive disease not permitting time to identify an unrelated donor.
* Donor cells should be collected and frozen before conditioning starts.

Exclusion Criteria:

* Patients with a life expectancy (\< or = to 6 weeks) limited by diseases other than leukemia.
* Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by echocardiogram (i.e. shortening fraction \< 25%)
* Patients with severe renal disease (i.e. creatinine clearance less than 40cc/1.73m2)
* Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of predicted)
* Patients with severe hepatic disease (direct bilirubin greater than 3ug/dl or SGPT greater than 500ug/dl)
* Patients with severe personality disorder or mental illness that would preclude compliance with the study
* Patients with a severe infection that on evaluation by the Principal Investigator precluded ablative chemotherapy or successful transplantation
* Patients with documented HIV positivity